Lv5
1260 积分 2024-02-25 加入
Minimal clinically important difference: defining what really matters to patients
9小时前
待确认
Navigating the complexities of drug development for inflammatory bowel disease
2个月前
已完结
Addressing the Challenge of Common Chronic Diseases — A View from the FDA
2个月前
已完结
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
3个月前
已完结
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
3个月前
已完结
Drift, Evolution, and Divergence in Biologics and Biosimilars Manufacturing
3个月前
已完结
FcγR Binding and ADCC Activity of Human IgG Allotypes
3个月前
已完结
Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms
3个月前
已完结
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
3个月前
已完结
Evolution of the EU Biosimilar Framework: Past and Future
3个月前
已完结
皖公网安备34019202002308
